Navigation Links
CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
Date:7/1/2008

INDIANAPOLIS, July 1 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced it closed a $25 million Series B financing. New investor Care Capital led the round, which included previous investors Pappas Ventures, Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures. The financing will be used to further develop a unique migraine compound, COL-144, and to advance a preclinical pipeline of novel chemical entities targeting neurological and psychiatric disorders.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5HT1F receptors expressed in the trigeminal nerve pathway. CoLucid completed a Phase II clinical trial last year examining the efficacy of COL-144 in the acute treatment of migraine after intravenous administration. The trial provided clear evidence of safe, effective alleviation of migraine pain and identified a range of doses that provided relief of migraine symptoms and were well tolerated. Based on these encouraging results, CoLucid is advancing clinical development of COL-144 as a treatment for migraine by the oral route of administration.

As a part of the Series B financing, CoLucid also announced the addition of Richard Markham, partner at Care Capital, to the Board of Directors. Prior to joining Care Capital, Markham held several senior leadership positions in the pharmaceutical industry, including CEO of Aventis Pharma, CEO of Hoechst Marion Roussel and President, COO and Board member of Marion Merrell Dow. In addition, he served as President and COO of Merck.

"COL-144 is the first in a new class of migraine therapeutics and represents a paradigm shift in the treatment of migraine," said James White, Ph.D., President and CE
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ption leads to success, study finds , ,...rcise, reduced soda consumption and self-weighing ...gies for adolescents, a new study shows. , Rese...t-control strategies and lifestyle habits. Sixty-t...The responses were grouped into four categories: ,...
(Date:12/4/2009)...patient groups , , FRIDAY, Dec. 4 (Healt... Ewing sarcomas and central nervous system tumors,...rs have found. , The study authors analyzed dat...on pediatric cancers who were enrolled in the Chil...found that the overall cancer recurrence rate was ...
(Date:12/4/2009)... to take breast cancer drug, study finds , ...out side effects are a major reason why only 6 per...cer are willing to take the drug tamoxifen to prev...ort to inform women about the risks and benefits o...igan Comprehensive Cancer Center created a decisio...
(Date:12/4/2009)...4 Today, seven of Florida,s top no...ng the health of Florida,s uninsured and underserv...2009 Sapphire Award ceremony. ,, The Sapphire A...izes and promotes organizations that have demonstr...ithin their communities. ,, Honorees of The 200...
(Date:12/4/2009)...re-FirstCall/ -- Movado Group Inc. (NYSE: MOV ),...a, Georgia, shared in a tribute on December 3, 200...ie Oudin for her stellar performance in the tourna...finalist at the Open since 1999. ,, (Photo: ...84 ) ,, At a celebratory reception held at Brow...
Breaking Medicine News(10 mins):Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
... May 20, 2009Physicians can and should play a lead...g towards comprehensive reform of the way health c...uaranteed 1.5 percent annual savings in health car...chieving Health Care ReformHow Physicians Can Help...
...al communities in California,s Central Valley , ,...re, one of the nation,s first and leading provider...of nephrology research, today announced their part...e Park in the City of Stockton. Satellite Healthca...
...ostatic intraepithelial neoplasia (HGPIN) carries ...ostate cancer. Research published in the open acce...atients whose extended core biopsy led to an initi...dation Trust and Lancaster University, along with ...
...hareholders to Support the Company,s Twelve Nomine..., Inc. (Nasdaq: AMLN ) today reminded its shareh...l of Amylin,s nominees, including its two new inde...bourne Capital Management, L.L.C. , , Amylin,s 20...
...., May 26 Cogdell Spencer Inc. (NYSE: CSA ) ann...lic offering of 18,000,000 shares of common stock....ters an option to purchase up to an additional 2,7...eds from the offering to fund a $50 million repaym...
...6 , , About Dr. Harold Kohn & Vimpat , A...l compound that affects neurological systems, Haro...hapel Hill , inventor of the recently FDA-approved... of perseverance, and Veronica was thrilled to tha...
Other Medicine News:Health News:Physicians can lead health care reform through payment and delivery system reforms 2Health News:Satellite Healthcare Walks for Kidney Health 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 2Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 3Health News:Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today 4Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 2Health News:Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug 3
(Date:12/4/2009)... 4 Chemistry World re... Pharmaceutical Research and Manufacturers of Ame...accines in development for HIV/AIDS and related co...products in development include 23 vaccines and 54...cal trials or awaiting approval by the U.S. Food a...
(Date:12/4/2009)...wire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: ...ntermeasures against biological and chemical threa... results of a study demonstrating the effectivenes... in the New Zealand White (NZW) rabbit. The data ...HHS Public Health Emergency Medical Countermeasure...
(Date:12/4/2009)...4 OrthoAccel Technologies, Inc., d...acceleration device to enhance orthodontics, annou...n course published by PennWell Corporation , a le..., including medicine and dentistry. The course fo..., a summary of treatment biomechanics, factors tha...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 1DURECT Corporation to Participate in Upcoming Healthcare Conferences 57474 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 1National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 2National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network 57469 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 1YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 14116 4
... a First-in-Class Biologic Treatment Option Now Av...s with JIA(1,2) -, PRINCETON, N.J., April 8, 2008... announced that the U.S. Food and Drug,Administrat...reducing signs,and symptoms in pediatric patients ...tive polyarticular juvenile idiopathic arthritis (...
...d., April 8, 2008 ImQuest scientists Robert,W. Bu...nted the results of,studies performed with product...ecent Microbicides 2008, an international conferen...icide scientists, developers, and care,givers from...ak by the,Conference organizers, presenting the re...
Other Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India 2
Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD
Protein A 50 OD, Colloidal Gold Conjugated/Tagged
Protein A, Gold Ribbon - .25 OD per sq. cm.
Protein G, Gold Ribbon - .50 OD per sq. cm.
Medicine Products: